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Epigallocatechin gallate (EGCG) is known to exhibit antioxidant, antiproliferative, and antithrombogenic effects and reduce the
risk of cardiovascular diseases. Key events in the development of cardiovascular disease are hypertrophy and hyperplasia according
to vascular smooth muscle cell proliferation. In this study, we investigated whether EGCG can interfere with PDGF-bb stimulated
proliferation, cell cycle distribution, and the gelatinolytic activity of MMP and signal transduction pathways on RAOSMC when
it was treated in two different ways—cotreatment with PDGF-bb and pretreatment of EGCG before addition of PDGF-bb. Both
cotreated and pretreated EGCG significantly inhibited PDGF-bb induced proliferation, cell cycle progression of the G0/G1 phase,
and the gelatinolytic activity of MMP-2/9 on RAOSMC. Also, EGCG blocked PDGF receptor-𝛽 (PDGFR-𝛽) phosphorylation
on PDGF-bb stimulated RAOSMC under pretreatment with cells as well as cotreatment with PDGF-bb. The downstream signal
transduction pathways of PDGFR-𝛽, including p42/44MAPK, p38MAPK, and Akt phosphorylation, were also inhibited by EGCG
in a pattern similar to PDGFR-𝛽 phosphorylation.These findings suggest that EGCG can inhibit PDGF-bb stimulated mitogenesis
by indirectly and directly interrupting PDGF-bb signals and blocking the signaling pathway via PDGFR-𝛽 phosphorylation.
Furthermore, EGCGmay be used for treatment and prevention of cardiovascular disease through blocking of PDGF-bb signaling.
1. Introduction
Several vascular diseases involve vascular smoothmuscle cell
(VSMC) proliferation as their primary mechanism. Dedif-
ferentiated VSMCs induce cell proliferation and migration,
as well as extracellular matrix (ECM) protein deposition
[1–4]. Intimal hyperplasia is an excessive tissue ingrowth
and chronic structural lesion that can be observed at the
site of atherosclerotic lesion formation, arterial angioplasty,
vascular graft anastomoses, and so forth. This phenomenon
is caused by the phenotype change of VSMCs from a
differentiated state to a dedifferentiated one. Several studies
have focused on VSMC phenotype switching, decreasing
expression of smooth muscle specific contractile markers
such as𝛼-smoothmuscle actin, smoothmusclemyosin heavy
chain, and calponin, [5, 6], migration and proliferation from
media to the intima, and extracellular matrix remodeling
[7, 8]. Vascular proliferation is the most important factor in
intimal hyperplasia and is linked to other cellular processes
such as migration, inflammation, and extracellular matrix
production.
Platelet-derived growth factor-bb (PDGF-bb) is one of
the most potent mitogens and chemoattractants for VSMC
andplays a central role via simultaneous interactions between
itself [9]. In previous studies, it was confirmed that PDGF-bb
induced phenotype switching [10, 11], MMP-2 upregulation
[12, 13], and migration [14] on VSMCs. PDGF-bb is also
known to bind to the PDGR receptor (PDGFR)-𝛽 and sub-
sequently activates several intracellular signaling cascades,
including the extracellular signal-regulated kinase (ERK),
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p38 mitogen-activated protein kinase (p38 MAPK) path-
ways, and phosphatidylinositol 3-kinase-Akt (PI3 K-Akt),
and stimulates VSMC dedifferentiation [15].
Epigallocatechin gallate (EGCG) is the most prevalent
polyphenol contained in green tea. This has been reported
to have antioxidant, antiproliferative, and antithrombogenic
effect. Recent experiments have suggested that green tea
catechins can reduce atherosclerotic lesions in various ani-
mal models and prevent cardiovascular diseases [16–18].
In addition, EGCG inhibits VSMC invasion by preventing
matrix metalloproteinase (MMP) expression and provides a
protective effect against atherosclerosis and cancer via matrix
degradation [19].
In this study, we investigated the effects of EGCG on pro-
liferation, cell cycle, and the intracellular signal transduction
pathway of PDGF-bb in rat aortic vascular smooth muscle
cell (RAOSMC) anddemonstrated the preventivemechanism
of PDGF-bb stimulated RAOSMC dedifferentiation.
2. Materials and Methods
2.1. Cell Culture. Rat aortic smooth muscle cells (RAOSMC)
were purchased from Biobud (Seoul, Republic of Korea), and
cells at passage 5 to 9 were used. The cells were routinely
maintained in Dulbecco’s Modified Eagle Medium (Gibco,
Carlsbad, CA, USA) and supplemented with 10% fetal bovine
serum (Sigma, St. Louis, MO, USA) and a 1% antibiotic-
antimycotic solution containing 10,000 units penicillin, 10mg
streptomycin, and 25𝜇g amphotericin B per mL (Sigma) at
37∘C in a humidified atmosphere of 5% CO
2
.
2.2. Cell Stimulation by PDGF-bb. EGCG (Teavigo), the
major polyphenolic constituent of green tea, was purchased
from DSM Nutritional Products Ltd. It was dissolved in 50%
DMSO (Sigma) for a stock solution of 100mM and then
diluted to the desired concentrations with media prior to cell
treatment. For the experiments, RAOSMCs were routinely
incubated. Cells were synchronized in serum-free medium
for 24 h before experiments. Prior to the experiments, the
cells were incubated with two different methods. With the
firstmethod, the synchronized RAOSMCswere preincubated
with EGCG in serum-free media for 24 h. Then, EGCG-
treated cells were washed twice with PBS and stimulated with
serum-free media containing 10 ng/mL of human recombi-
nant PDGF-bb (Sigma) for a desired length of time. For
the second method, cells were synchronized in serum-free
DMEM medium for an additional 24 h and stimulated with
10 ng/mL PDGF-bb and soluble EGCG.
2.3. Cell Proliferation and DNA Synthesis. Cell prolifer-
ation was determined by MTT assay (reduction of 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
to a purple formazan product, Sigma) and a 5-bromo-2󸀠-
deoxyuridine (BrdU) incorporation assay (Roche Applied
Science, Seoul, Republic of Korea).
For the MTT assay, the cells incubated with 0.5mg/mL
of MTT in the last 4 h of the culture period were tested at
37∘C in the dark.Themedia were decanted, and the produced
formazan salts weredissolved with dimethylsulphoxide, and
absorbance was determined at 570 nm by an automatic
microplate reader (Spectra Max 340, Molecular Devices Co.,
Sunnyvale, CA, USA).
For BrdU incorporation assay, BrdU-labeling solution
was added to the cells, and it was reincubated for 2 h at 37∘C.
Labeling mediumwas then removed, and the cells were incu-
bated with fixated solution for 30min at room temperature.
After fixation of the cells, anti-BrdU-POD working solution
was added, and the cells were incubated for 90min at room
temperature. Then, the substrate solution was added, and
absorbance was measured at 370 nm with 492 nm reference
wavelength by an automatic microplate reader (Spectra Max
340, Molecular Device Co.)
2.4. Cell Cycle Analysis. To analyze the cell cycle, RAOSMCs
were collected and washed with cold phosphate-buffered
saline (PBS, pH 7.2). The cells were resuspended in 95% cold
methanol for 1 h at 4∘C and then centrifuged at 120×g for
5min. The resultant pellet was washed twice with cold PBS
and incubated with RNase A (20U/mL final concentration,
Sigma) at 37∘C for 30min. Intracellular DNA was labeled
with 100 𝜇g/mL propidium iodide (PI, Sigma) for 1 h and
then analyzed with a fluorescence-activated cell sorter (FAC-
SCalibur, Becton Dickinson, San Jose, CA, USA). The cell
cycle profile was gained by analyzing at least 20,000 cells
with the ModFit LT program written by Mac-App (Becton
Dickinson).
2.5. Gelatin Zymography. Gelatinase activity was detected in
the conditioned medium of cultured RAOSMC. The condi-
tionedmediamixed with Laemmli buffer under nonreducing
conditions were loaded onto 10% SDS-polyacrylamide gel
containing 0.1% gelatin. After electrophoresis, the gels were
washed for 20min at room temperature in 2.5% Triton X-100
and incubated for 18 h at 37∘C with reaction buffer (50mM
Tris base (pH7.6), 0.2M NaCl, 5mM CaCl
2
, 0.02% Brij 35).
The gels were stained with Coomassie Brilliant Blue R-2500
(0.1%) and destained. Densitometric analysis was performed
with imageJ software (National Institutes ofHealth, Bethesda,
MD, USA).
2.6. Western Blot Analysis. After being stimulated with
PDGF-bb, the cells were washed twice with cold PBS (10mM,
pH 7.4). Ice-cold RIPA lysis buffer (Santa Cruz Biotechnology
Inc., Santa Cruz, CA, USA) was added to the cells and
incubated for 5min.The cells were scraped, and the lysate was
cleared by centrifugation at 14,000×g for 20min at 4∘C. The
resultant supernatant (total cell lysate) was collected. Protein
concentration was determined by using a DC Bio-Rad assay
kit (Bio-Rad Laboratories Inc., Hercules, CA, USA). For
immunoblot analysis, the protein was run on SDS-PAGE
and then electrotransferred onto a PVDF membrane. The
membrane was blocked with the buffer (5% nonfat dry milk
and 1% Tween-20 in 20mMTBS, pH 7.6) for 1 h at room tem-
perature and then probed overnight with phospho-PDGFR-
𝛽 (p-PDGFR-𝛽), PDGFR-𝛽, phospho-MEK1/2 (p-MEK1/2),
MEK1/2, phospho-p42/44MAPK (p-p42/44MAPK), p42/44
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Figure 1: The antiproliferative activity and cell cycle arrest activity by PDGF-bb on EGCG preincubated RAOSMC. After 24 h of starvation
with DMEM containing increasing concentrations (10–80𝜇M) of EGCG, cells at 80% confluence were washed and treated with 10 ng/mL
PDGF-bb. (a) The effects of growth inhibition on PDGF-bb stimulation in EGCG preincubated RAOSMC. Cell viability was detected using
the MTT assay. ∗𝑃 < 0.05 compared with nonstimulation control; #𝑃 < 0.05 compared with the 10 ng/mL PDGF-bb stimulated control.
(b) The effect of EGCG preincubation on PDGF-bb-induced DNA synthesis in RAOSMC. DNA synthesis was detected using the BrdU
incorporation assay. ∗𝑃 < 0.05 compared with nonstimulation control; #𝑃 < 0.05 compared with 10 ng/mL PDGF-bb stimulated control. (c)
EGCG preincubation with PDGF-bb stimulated cell cycle distribution in RAOSMC. Cell cycle distribution was determined by propidium
iodide (PI) labeling followed by flow cytometry. The percentages of cells in the G0/G1, S, and G2/M phases were calculated using Modifit
computer software and represented within the histograms.
MAPK, phospho-Akt (p-Akt), Akt, phospho-p38 MAPK (p-
p38 MAPK), and p38 MAPK used at a 1 : 1,000 dilution from
Cell Signaling Technology (Danvers,MA,USA). Detection of
horseradish peroxidase-conjugated secondary Ab (e.g., anti-
rabbit IgG (1 : 5,000) and anti-mouse IgG (1 : 2,000) from
Santa Cruz Biotechnology Inc.) was accomplished using
enhanced chemiluminescence using the ECL Plus detection
kit (Amersham Biosciences, Buckinghamshire, England).
Densitometric analysis was performed with imageJ (National
Institutes of Health, Bethesda, MD, USA).
2.7. Statistical Analysis. All variables were tested in three
independent cultures for each experiment. The results are
reported as a mean ± SD and compared to non-treated
controls. Statistical analysis was performed using a one-
way (ANOVA), followed by a Tukey HSD test for multiple
comparisons using SPSS software. A 𝑃 value of <0.05 was
considered statistically significant.
3. Results
3.1. Inhibitory Effect of Proliferation by PDGF-bb on EGCG
Pretreated RAOSMC. To investigate proliferation by PDGF-
bb stimulation on RAOSMC pretreated with EGCG, increas-
ingEGCGconcentrationwas treatedwith serum-freeDMEM
for 24 h at 70∼80% confluence RAOSMC. Cells were then
washed twice with PBS and incubated with 10 ng/mL PDGF-
bb for 24 h. 10 ng/mL PDGF-bb induced a significant (𝑃 <
0.05) RAOSMC proliferation as compared to the nonstim-
ulated group as assessed by increased DNA synthesis and
increased formazan absorbance. When cells were preincu-
bated with increasing concentrations of EGCG, cell prolif-
eration by 10 ng/mL PDGF-bb was significantly (𝑃 < 0.05)
decreased in a dose-dependent manner of EGCG.Therefore,
cell viability (Figure 1(a)) and DNA synthesis (Figure 1(b))
were not significantly affected in concentrations up to 50𝜇M.
To investigate the effects of EGCG pretreatment on cell
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Figure 2: Antiproliferative activity and cell cycle arrest activity of PDGF-bb with EGCG on RAOSMC. After 24 h of starvation with serum-
free DMEM, the cells were treated with 10 ng/mL PDGF-bb and increasing concentrations (10–80𝜇M) of EGCG for 24 h. (a) The effects
of EGCG growth inhibition on PDGF-bb stimulation in RAOSMC. Cell viability was detected using an MTT assay. ∗𝑃 < 0.05 compared
with nonstimulation control; #𝑃 < 0.05 compared with the 10 ng/mL PDGF-bb stimulated control. (b) The effects of EGCG on PDGF-
bb-induced DNA synthesis in RAOSMC. DNA synthesis was detected using the BrdU incorporation assay. ∗𝑃 < 0.05 compared with
nonstimulation control; #𝑃 < 0.05 compared with 10 ng/mL PDGF-bb stimulated control. (c) The effect of EGCG on PDGF-bb stimulated
cell cycle distribution in RAOSMC. Cell cycle distribution was determined by propidium iodide (PI) labeling followed by flow cytometry.
The percentages of cells in the G0/G1, S, and G2/M phases were calculated using Modifit computer software and represented within the
histograms.
cycle distribution, DNA cell cycle analysis was performed on
RAOSMCstimulatedwithPDGF-bb.As shown in Figure 1(c),
EGCG pretreatment resulted in an appreciable increase in
cells in the G0/G1phase, with a decrease in S-phase cells
in up to 20𝜇M EGCG pretreatment. These results indicate
that EGCG pretreatment can suppress cell cycle progression
and cell growth on RAOSMC with distributed PDGF-bb
stimulation.
3.2. Inhibitory Effect of Proliferation by Cotreatment of PDGF-
bb and EGCG on RAOSMC. To investigate proliferation by
PDGF-bb stimulation with EGCG on RAOSMC, synchro-
nized cells were incubated for 24 h with increasing concen-
trations of EGCG and 10 ng/mL PDGF-bb. Cotreatment with
EGCG and PDGF-bb significantly inhibited the proliferation
of RAOSMC by PDGF-bb stimulation (Figure 2(a)). Simi-
larly, Figure 2(b) shows that DNA synthesis is also inhibited.
According to BrdU incorporation into RAOSMC, cotreat-
ment of EGCG (10 𝜇M) and PDGF-bb represented more
inhibitory effects than pretreatment of EGCG. Proliferation
was completely inhibited at a concentration of 50 𝜇MEGCG.
EGCG induced a significant accumulation of the cells in the
G0/G1 phase of the cell cycle at up to 10 𝜇M. Inhibition of cell
growth in RAOSMCmay be caused byG0/G1 arrest as EGCG
interrupts PDGF-bb stimulated cell cycle progression.
3.3. Preventive Effect of Active MMP-2/9 Production by
EGCG on PDGF-bb Stimulated RAOSMC. MMP-2 and
MMP-9 were detected in the conditioned media from
cultured RAOSMC for 24 h with EGCG and PDGF-bb
by gelatin zymography assay. After stimulation with
PDGF-bb, RAOSMC showed more pro-MMP conversion
into the intermediated and active form of MMP-2, and
increased the MMP-9 release. As shown in Figure 3, EGCG
pretreated RAOSMC significantly reduced the PDGF-
bb-induced gelatinolytic activities of active MMP-2 and
MMP-9. Therefore, the stimulatory effect of PDGF-bb also
caused a reduction in MMP-2/9 gelatinolytic activity in a
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Figure 3: Inhibitory effect of EGCG on PDGF-bbinduced MMP gelatinolytic activity in RAOSMC. Gelatin catalytic activity was analyzed
by gelatin zymography using conditioned medium. The band intensity was normalized by densitometry. PDGF-bb induced the gelatinolytic
activity of MMP-9 and MMP-2. However, both preincubated and coincubated EGCG inhibited secretion of PDGF-bbinduced MMP-9 and
MMP-2 activity.
concentration-dependent manner by treatment of RAOSMC
with EGCG. The inhibitory effect of MMPs gelatinolytic
activity was dose-dependently expressed on EGCG. The
active form of MMP-2 was not detected at up to 20𝜇M of
EGCG.
3.4. Inhibitory Effect of PDGF-bb Stimulated Signal Trans-
duction Pathway in EGCG Preincubated RAOSMC. To define
the effects of EGCG pretreatment on signaling path-
ways of PDGF-stimulated mitogenesis, already synchronized
RAOSMCs were incubated with EGCG and serum-free
media for 24 h. For PDGF-bb stimulation, the cells were
washed using PBS to remove EGCG, incubated for the
desired time, and examined for levels of various proteins
by Western blot analysis. Addition of 10 ng/mL PDGF-bb
to serum-starved RAOSMCs led to complete PDGFR-𝛽
phosphorylation, which reached the peak within 10min and
then decreased to nearly baseline levels at 240min. However,
pretreated EGCG suppressed PDGFR-𝛽 phosphorylation by
PDGF-bb and sustained only baseline level (Figure 4(a)).
The phosphorylations of MEK1/2 and p42-44MAPK, down-
stream proteins of PDGF-induced signaling, were signifi-
cantly increased between 10 and 30min and declined over
the following 240min. However, pretreated EGCG inhibited
MEK1/2 and p42-44MAPK phosphorylations in a time-
dependent manner, similar to PDGFR-𝛽 phosphorylation
(Figure 4(b)). In the other intracellular signal pathways,
phosphorylations of Akt and p38 MAPK were activated by
PDGF-bb stimulation. However, the Akt and p38 MAPK
phosphorylations induced by PDGF-bb were inhibited in
RAOSMCs by being pretreated with EGCG (Figure 4(c)).
These results suggest that EGCG can indirectly inhibit the
phosphorylation of PDGFR-𝛽 by PDGF-bb.
3.5. Inhibitory Effect of Signal Transduction Pathway on
RAOSMC by PDGF-bb Stimulation with EGCG. To charac-
terize the signaling pathways by direct interaction between
EGCG and PDGF-bb, serum-starved RAOSMCs were incu-
bated with EGCG and PDGF-bb for the desired times.
PDGFR-𝛽 phosphorylation was completely suppressed and
inactivated on PDGF-bb induced RAOSMC by EGCG com-
paredwith the PDGF-stimulated samples that were processed
on the same blot (Figure 5(a)).Therefore,MEK1/2 and p42/44
MAPK phosphorylations were suppressed and sustained at
baseline levels by being cotreated EGCG with PDGF-bb
(Figure 5(b)). The phosphorylations of Akt and p38 MAPK
were also suppressed by inhibition of PDGF-bb signaling by
EGCG.These results reveal that EGCG can directly interrupt
PDGF-bb stimulation by inhibiting PDGFR-𝛽 phosphoryla-
tion.
4. Discussion
PDGF-bb is a major stimulator of VSMC dedifferentiation
and is known to play a central role in the pathogenesis
of various vascular disorders. Signal transduction pathways
involve the activation of mitogen-activated protein kinases
(MAPKs) on PDGF-induced responses. MAPK is a family of
serine/threonine protein kinases with 3 subfamilies named c-
jun-N-terminal kinase 1/2 (JNK1/2), ERK1/2, and p38MAPK.
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Figure 4: Modulation of PDGF-bb stimulatory signal pathways on EGCG preincubated RAOSMC. RAOSMC preincubated with EGCG was
stimulated with 10 ng/mL PDGF-bb for the desired time (10m, 30m, 1 h, 2 h, and 4 h, resp.), lysed, and lysates were immunoblotted with
antibodies. After densitometric quantification, data were each expressed as the mean ± SD from three independent experiments. The black
bars indicate expression by PDGF-bb stimulation.Thewhite bars indicate expression by PDGF-bb stimulation onEGCGpretreatedRAOSMC.
(a) The expression of phospho-PDGFR-𝛽 (Tyr751) in a time-dependent manner. The band intensity was normalized to total PDGFR-𝛽
expression. (b)The expression of phospho-MEK1/2 (Ser217/221) and phospho-p42/44MAPK (Thr202/Tyr204) in a time-dependent manner.
The band intensity was normalized to totalMEK1/2 and p42/44MAPK expression. (c)The expression of phospho-Akt (Thr308) and phospho-
p38 MAPK (thr180/Tyr182) in time-dependent manner. The band intensity was normalized to total Akt and p38 MAPK expression.
PDGF stimulated rapid and significant activation of Akt,
ERK1/2, and p38 MAPK in cultured VSMC. MAPKs are
proposed to play amajor role in the activation of various tran-
scription factors [20, 21]. PDGF-bb binds with PDGFR-𝛽 and
triggers receptor dimerization and autophosphorylation at
tyrosine residues that activate the kinase and serve as recruit-
ment sites for SH2 domain-containing proteins. Within
minutes, many signaling modules are engaged, including
Ras, Src, phosphoinositide 3󸀠-kinase (PI3 K), SHP2, and
phospholipase C𝛾 (PLC𝛾) [9, 22, 23]. Downstream signals
then activate PI3-K/PKB (Akt) and two MAPK pathways
[24]. VSMC dedifferentiation is determined by activation
of Akt pathway, p42/44 MAPK, and p38 MAPK pathways.
Ultimately, this results in VSMC dedifferentiation via the
recruitment, and activation of specific signaling pathway
may mediate the migration and proliferation of VSMCs in
response to injury such as the development of atherosclerosis
and hypertension. Several studies have revealed that PDGFR
targeted by synthetic tyrosine kinase inhibitors and antisense
treatment reduce neointima formation in injured arteries
[25, 26].
EGCG has been shown to have protective effects on the
cardiovascular system, including antiatherosclerotic, antihy-
percholesterolemic, and antirestenosis effects [27–29]. Also,
several studies have stated that EGCG inhibited prolif-
eration, migration, and invasion of barrier by inhibition
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Figure 5:The effect of EGCGonmodulation of PDGF-bb stimulatory signal pathways in RAOSMC. Serum-starved RAOSMCwas stimulated
with 10 ng/mLPDGF-bb and 50𝜇MEGCG for the desired time (10m, 30m, 1 h, 2 h, and 4 h, resp.), lysed, and lysateswere immunoblottedwith
antibodies. After densitometric quantification using the imageJ program, data were each expressed as the mean ± SD from three independent
experiments. The black bar indicates expression by PDGF-bb stimulation. The white bar indicates expression by PDGF-bb stimulation with
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via intracellular signaling transduction pathway signals on
VSMC stimulated with growth factor, such as angiotensin
II [30, 31] and basic fibroblast growth factor (bFGF) [32].
A previous study showed that EGCG induced apoptosis of
VSMCs in a p53- and NF-𝜅B-dependent manner [33, 34].
However, the dosage of polyphenols and flavonoids in cell
culture studies may be much higher that than which occurs
after oral administration in the body. The compounds may
losemost of their functions after undergoingmetabolism and
circulation in vivo, but this may not be possible to evaluate
in vitro. For that reason, concentration determined by in
vitro experiment may be difficult to apply as a physiological
dose to animals or humans [35–37]. Although not all cell
culture findings are applicable for animal experiments, in
vitro studies have provided important insights into the action
mechanisms of flavonoids that would be physiologically
achievable in human [37].
Polyphenolic catechins and flavonoids are generally safe
and may possess beneficial properties for human health.
Various clinical studies have revealed that they are effective
at various organ sites [38]. However, unusually high dosage
of natural products supplements may exhibit toxicity in vivo
[36, 37]. Accordingly, numerous studies have been performed
to improve the stability and enhance the physiological activity
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of native compounds, with combination with other agents,
synthetic modification, and adoption of analog and prodrug
[39, 40].
Our results observed that RAOSMC stimulation by
PDGF-bb induced proliferation and cell cycle progression
through intracellular pathways: p42/44 MAPK, p38 MAPK,
and Akt cascade, in addition to the activation of PDGFR-𝛽.
However, PDGF-bb did not induce proliferation and mito-
genesis on RAOSMC preincubated with EGCG (Figure 1).
Also, pretreated EGCG inhibited the gelatinolytic activity of
MMP-9 and conversion from pro-MMP-2 to active MMP-2.
Therefore, gelatinolytic activity of MMPs was inhibited dose-
dependently in PDGF-bb stimulated RAOSMCs by EGCG
(Figure 3). Previous studies reported that EGCG enhanced
pro- and active MMP-2 binding to TIMPS and upregulated
TIMP-2 expression as one of the major mechanisms for
inhibition of SMC invasion [16, 41]. These results suggest
that EGCG regulates the activation of MMPs and TIMPs for
inhibition of invasion in dedifferentiated VSMCs.
These results suggest that EGCG may mediate the inhi-
bition of PDGF-bb directly binding with PDGFR-𝛽 on the
RAOSMC membrane of RAOSMC and thus deactivate the
PDGF signal pathway related to mitogenesis (Figure 4).
Some studies reported that EGCG is hijacked by the laminin
receptor (LamR), a lipid raft protein, and alters membrane
domain composition to prevent epidermal growth factor
(EGF) from binding to its receptor (EGFR) [42, 43]. Also,
EGCG has been shown to incorporate itself into the plasma
membrane to lead to reversible binding of PDGF-bb to
a nonreceptor target site, reducing PDGF binding to its
receptors [44]. Thus, EGCG inhibits a surface-membrane
linked mechanism [45].
In this study, we could also demonstrate on the direct
interaction between EGCG and PDGF-bb when they are
cotreated. As shown in Figure 2, low concentration of EGCG
(10 𝜇M) induces antiproliferation and cell cycle arrest, and
cell stimulation occurred in the presence of EGCG. This
effect is accompanied by the fact that EGCG inhibits PDGF-
induced mitogenesis by disturbing PDGFR-𝛽 phosphoryla-
tion (Figure 5). Also, the inhibitory effect of EGCG was
mediated by the blockage of PDGFR-𝛽 phosphorylation
early in the experiment. Thus, EGCG may already have
interacted with PDGF-bb in media and inhibited VSMC
dedifferentiation by blocking the early signal transduc-
tion pathway. Other research groups showed that EGCG
is able to interact with various biomolecules, especially
proliferation-related proteins, each being proved by various
cell line experiments [46–51]. Therefore, recent studies have
revealed that EGCG binds with high affinity to residues
located in the serum albumin under physiological conditions
[52, 53].
Based on our findings, we suggest that EGCG inhibits
RAOSMC mitogenesis by interruption of PDGF-bb signal-
ing, probably by blockage of PDGF-bb binding and PDGFR-
𝛽 phosphorylation, as well as the activation of p42/44
MAPK, p38 MAPK, and Akt, important downstream events
of PDGFR-𝛽. Therefore, EGCG may be a potential target for
inhibiting PDGFR and may be of use in the prevention and
treatment of vascular diseases.
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